Evidence map›Paper›PMID 39864419›Full record

ArticleAudiology & neuro-otology2025

Concentration Dependent Effects of Human Cometin on Spiral Ganglion Neuron Survival and Neurite Outgrowth.

Jana Schwieger, Chunjiang Wei, Gordon Munro, Kenneth Ahrend Petersen, Thomas Lenarz, Verena Scheper, Jana Schwieger

Abstract read
In one paragraph

Article in Audiology & neuro-otology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Neural Hearing Loss: Mechanisms, Diagnosis and Treatment Horizons.Journal of the Association for Research in Otolaryngology : JARO · 2026
    Review
  3. Frontiers in bioengineering and biotechnology · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jana SchwiegerDepartment of Otorhinolaryngology, Hannover Medical School, Hannover, Germany.
Chunjiang WeiDepartment of Otorhinolaryngology, Hannover Medical School, Hannover, Germany.
Gordon MunroHoba Therapeutics ApS, Copenhagen, Denmark.
Kenneth Ahrend PetersenHoba Therapeutics ApS, Copenhagen, Denmark.
Thomas LenarzDepartment of Otorhinolaryngology, Hannover Medical School, Hannover, Germany.
Verena Scheper
Jana Schwieger

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Introduction: Neurotrophic factors are widely known for their protective effect on spiral ganglion neurons (SGN) and the protection of these neurons is of great importance to optimize cochlear implants, which directly stimulate SGN in deaf patients. Previous studies have identified Cometin - also known as Meteorin-like - to be neuroprotective and beneficial for metabolic disorders. The aim of our study was to investigate the effects of different concentrations of recombinant human Cometin (hCometin) on SGN in regard to neuroprotection and neurite outgrowth and to evaluate its neurite guidance potential using a neurite outgrowth chamber.

methodshCometin was initially tested in two separate dosing experiments: 5, 10, and 15 μg/mL (medium dose group) and 10, 25, and 50 μg/mL (high dose group). The hCometin was added to dissociated neonatal murine SGN. The number, morphology, and neurite length of SGN treated with hCometin were compared to untreated (negative control, NC) and brain-derived neurotrophic factor treated (BDNF, 50 ng/mL) (positive control, PC) cells. Subsequently, to investigate a potential effect on neurite guidance, 10 μg/mL hCometin was delivered via osmotic pumps to neonatal murine spiral ganglion explants (SGE) cultured in a neurite outgrowth chamber to experimentally mimic the scala tympani and the Rosenthal's canal. The amount of pump-released hCometin was measured by enzyme-linked immunosorbent assay and neurite growth was quantified and compared to a Cometin-free NC.

resultsAll medium dose group concentrations of hCometin resulted in significant neuronal protection, whereas high dose group concentrations (25 and 50 μg/mL) were neurotoxic. The medium dose concentrations significantly increased the number of monopolar neurons compared to NC, and 10 and 15 μg/mL hCometin increased the number of neurons with a physiological bipolar morphology to an even greater extent than BDNF. For neurite length, 5 and 10 μg/mL hCometin had the greatest effect, which was comparable with the BDNF-PC. The osmotic-pump based delivery of 10 μg/mL hCometin to SGE had no positive effect on the number, extent, or orientation of outgrowing neurites in the culture set up used.

conclusionA concentration of 10 μg/mL hCometin significantly protects dissociated SGN from degeneration and significantly increases the outgrowth of neurites, which is favourable in view of induced neurite outgrowth towards cochlear electrode arrays for future optimisation of the nerve-electrode-interface. The study failed to detect a guided neurite outgrowth by pump-based drug release, which may be due to the experimental set up, which could be improved in future studies. </p>.

Indexed as

NeuritesNeuronal OutgrowthNeuronsNeuroprotective AgentsSpiral GanglionAnimalsBrain-Derived Neurotrophic FactorCells, CulturedCell SurvivalDose-Response Relationship, DrugHumansMiceBrain-Derived Neurotrophic FactorNeuroprotective AgentsCochlear implantGrowth factorMeteorin-likeNeuronal protectionSpiral ganglion neuron

Identifiers

PMID39864419
PMCPMC12360724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.